Recent Security Class Actions

NeoGenomics Inc. Common Stock (NASDAQ: NEO)

Company Name:NeoGenomics Inc. Common Stock
Stock Symbol:NASDAQ: NEO
Class Period Start:02/27/2020
Class Period End (inclusive):04/26/2022
Filing Deadline:02/06/2023

The Complaint alleges that during the class period, Defendants made false and misleading statements or failed to disclose the following: (1) Defendants represented to investors that they had a “comprehensive menu” of cancer tests with “every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,” which positioned the Company as a “one-stop-shop” for pathologists and gave NeoGenomics “a competitive advantage” as a “go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer” and (2) Defendants represented that NeoGenomics could “leverage” the supposedly “fixed cost” structure of its business to improve profitability as revenue increased and touted the Company’s “robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.”